Introduction {#Sec1}
============

Gastroschisis (GS) is the leading cause of pediatric intestinal failure and intestinal transplantation. GS intestinal injury results in edema, ileus, failure of intestinal defense mechanisms and severe intestinal dysfunction. GS-related intestinal dysfunction (GRID) delays full enteral autonomy and increases morbidity that is associated with prolonged hospital stays \[[@CR1]--[@CR3]\].

Normal intestinal motility is regulated by active and passive mechanical properties. Active mechanical properties include smooth muscle tone, phasic contractility and luminal fluid flow \[[@CR4]\]. Smooth muscle tone is important in the initiation and maintenance of peristalsis and propagation of food content \[[@CR5]\]. Smooth muscle hypertrophy, collagen deposition and delayed smooth muscle maturity are characteristics of GS intestinal injury, and some studies suggest that these characteristics alter the active mechanical properties which may result in GRID \[[@CR1], [@CR6], [@CR7]\].

Two risk factors for GRID development have been identified in humans and animal models: (1) the mesenteric constriction of GS abdominal wall defect and (2) intestinal exposure to amniotic fluid (AF). Based on these risk factors, we developed a postnatal rat model to study whether the mechanical influence of the abdominal wall defect would cause GRID \[[@CR8]\]. We found simulating the abdominal wall defect elevated the mesenteric venous pressure producing non-occlusive mesenteric venous hypertension (NMH). NMH without the presence of AF contributed to intestinal dysmotility, smooth muscle hypertrophy and bowel shortening recreating GRID in our model.

Pro-inflammatory mediators have been shown to impair intestinal motility in a variety of settings in animal models. Our model also provided evidence that NMH produced intestinal inflammation \[[@CR9]--[@CR12]\]. Transforming growth factor-beta (TGF-β), an inflammatory cytokine, has been associated with a number of human smooth muscle diseases such as asthma and atherosclerosis. These disorders exhibit smooth muscle migration, hypertrophy, hyperplasia, extracellular matrix deposition and inflammation as a part of end-organ remodeling and dysfunction, a characteristic shared with GRID. Using cDNA microarray, we found that the intestine in NMH animals had increased gene expression of TGF-β proteins and receptors. We confirmed this finding by staining the intestine for TGF-β proteins and found that the intestinal smooth muscle cells had increased levels of TGF-β3 (unpublished data). Since limited data exist on TGF-β3′s role in the intestine, we hypothesized that TGF-β3 is an important signal for intestinal smooth muscle dysfunction promoting the GRID phenotype.

Materials and Methods {#Sec2}
=====================

The University of Texas Animal Welfare Committee approved all procedures according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The University of Texas Institutional Review Board approved all human studies performed in this study.

Reagents and Devices {#Sec3}
--------------------

The following cells and reagents were used in our experiments: Sprague--Dawley rats (Harlan Labs, Indianapolis, Indiana, USA), human intestinal smooth muscle cells (hiSMC, ScienCell), smooth muscle cell medium (FBS, ScienCell), Dulbecco's phosphate-buffered saline (DPBS, Thermo Scientific), human TGF beta 1 and TGF beta 2 (TGF-β1 & β2 (100 ng/ml), Biolegend) and TGF-β3 (TGF-β3 (100 ng/ml), Prospec) recombinant proteins, rabbit polyclonal antibody to all TGF-βs (Abcam), mouse monoclonal antibody α-smooth muscle actin (α-SMA, Abcam), cell dissociation solution (Mediatech, 25-056CI), Alexa Fluor^®^ goat anti-mouse IgG (H + L) highly cross-adsorbed secondary antibody (Life technologies), Alexa Fluor^®^ goat anti-rabbit IgG (H + L) highly cross-adsorbed secondary antibody (Life technologies), 4',6-diamidino-2-phenylindole (DAPI, Life technologies) and rat tail collagen I (BD Biosciences). Western blot signals were detected by using Kodak image station 4000R. Micro-RNA materials included: miRNeasy FFPE and miScript II RT kits (Qiagen) and miRNA assays (SA Biosciences, Valencia, CA).

### TGF-β Isoform Immunohistochemistry {#Sec4}

#### Human Intestinal Tissue {#Sec5}

We obtained archived intestinal tissue samples from infants with GS that underwent surgical resection secondary intestinal atresia. GS infants that had intestinal volvulus or perforation and/or necrotic segments were excluded from evaluation. We used intestinal tissue from age-matched infants that died without intestinal pathology for our control tissue. We evaluated the pathologist's autopsy reports to determine whether the tissue sections were taken from healthy intestinal tissue segments. After deparaffinization and antigen recovery, slides were incubated at 4 °C overnight with a primary TGF-β1, 2 or 3 antibody and co-stained with α-actin antibody. The slides were then incubated for 1 h with a PE-conjugated fluorescent secondary antibody. The slides were then stained with DAPI for nuclear visualization, and 2D deconvolution microscopy was utilized to visualize TGF-β isoforms and α-actin localization staining.

Functional Studies {#Sec6}
------------------

### Determination of Smooth Muscle Contractility in Cell Culture {#Sec7}

Primary hISMCs were suspended (500,000 cells/mL) in a rat tail collagen I solution (2 mg/mL), and FBS was added to the diluent. 1 N NaOH 0.023 × collagen stock volume was used to adjust pH to neutral immediately after cells were added. TGF-β1, 2 or 3 was added to the mixture. A 250 μl cell suspension was dispensed into a 48-well plate. The collagen gel was allowed to solidify at 37 °C for 30 min. After loosening the gel from each well, we added 250 μl FBS ± TGF-β1, 2 or 3 to the wells and imaged the gels using a Kodak image station 4000R at 6, 24 and 72 h.

### Determination of Intestinal Transit in Rats {#Sec8}

Male neonatal Sprague--Dawley rats, weighing between 40 and 60 g, were fasted 10--12 h prior intraperitoneal (i.p.) injection of low dose (0.2 mg/kg) or high dose (1 mg/kg) of recombinant TGF-β3 protein. Intestinal transit was measured at 12 h after i.p. injection of TGF-β3 according to our previously published methods \[[@CR8]\]. Intestinal transit is determined by the distribution of a non-absorbable 70-kDa fluorescein isothiocyanate-labeled dextran (FD70). Briefly, 200 µL of 2.5 mg/ml solution (dissolved in distilled water) was administered by oral gavage. After 60 min, the supernatant from the effluent from the intestinal segments was collected and assessed fluorometrically for concentration of FD70. Transit was evaluated by calculating the geometric center of distribution of FD70 (∑ ((fluorescent signal per segment (percent) × segment number)/100).

### Gene Expression Studies {#Sec9}

#### Cell Culture Techniques {#Sec10}

Human intestinal smooth muscle cells were maintained in DMEM supplemented with 10 % fetal bovine serum at 37 °C in a humidified atmosphere of 5 % CO~2~. Early passage cells (passage 1--3) were used. Cells were grown to 90 % confluence in DMEM-10 % fetal bovine serum ± TGF-β3 at 6, 24 and 72 h. The cells were harvested for the isolation of total RNA (contractile/synthetic phenotype expression) and miRNA (remodeling phenotype expression) using a commercially available kit.

#### Laser Capture Microdissection Microscopy {#Sec11}

We obtained archived intestinal tissue samples from patients that with Gastroschisis (GS), intestinal atresia (IA), necrotizing enterocolitis (NEC) and age-matched premature infant control tissue. We added the IA and NEC groups secondary to the method used to calculate miRNA-143/145 expression. The age-matched controls were used as our control reference. We used these samples to perform the laser capture microdissection (LCM) of the small intestine smooth muscle layer. Separate sections of formalin-fixed paraffin-embedded specimens were oriented to provide cut sections parallel with the longitudinal axis of the bowel. Ten micrometer tissue slices were mounted and stained with H&E. Five slides per human sample were used. The slides were then deparrafinized with xylene and graded concentrations of ethanol. The Applied Biosystems^®^ ArcturusXT™ Laser Capture Microdissection System was used for laser capture and operated as instructed by the manufacturer. This is a unique combination of infrared (IR) laser-enabled LCM and ultraviolet laser cutting in one platform used for the isolation of specific cell types from heterogeneous tissue samples. We isolated the muscularis mucosae and muscularis externa alone from the small intestine. The cells were transferred to a polymer film (CapSure^®^ HS LCM Caps). After collecting the cells of interest, the samples were processed immediately for microRNA (miRNA) isolation and analysis using the miRNeasy FFPE kits.

Contractile and Synthetic Phenotypic Determination in Gastroschisis and Human Intestinal Smooth Muscle Cell Culture {#Sec12}
-------------------------------------------------------------------------------------------------------------------

Gene-specific primers and target-specific miRNA assays to determine contractile versus synthetic gene expression were adapted from the vascular smooth muscle literature \[[@CR13], [@CR14]\] and are listed in Table [1](#Tab1){ref-type="table"}. Real-time quantitative polymerase chain reaction (RT-PCR) using SYBR^®^ Green was performed to monitor changes in messenger RNA (mRNA) gene expression from our human intestinal smooth muscle cell culture at 6, 24 and 72 h. Relative mRNA expression ratios were normalized to human GAPDH and expressed as a fold change compared with 6-h sample.Table 1Gene-specific primers used in RT-PCRDescriptionRefseq accession\#Contractile phenotype gene markersActin, gamma 2, smooth muscle, enteric (ACTG2)NM_001615Calponin 1, basic, smooth muscle (CNN1)NM_001299Myosin, heavy chain 10, non-muscle (MYH10)NM_005964Smooth muscle 22-α (TAGLN)NM_003186miR143NR_027180miR145NR_029686Synthetic phenotype gene markersVimentin (VIM)NM_003380L-Caldesmon (CALD1)NM_004342Myosin, heavy chain 11, smooth muscle (MYH11)NM_022844

miRNA isolated from cell culture and LCM-captured muscularis was re-suspended in RNase-free H~2~O and then analyzed using the Agilent 2100 bioanalyzer to assess the integrity of total RNA. Once the samples were identified to have viable RNA, we reverse-transcribed the total RNA containing miRNA using the miScript II RT kit. The reactions were then loaded onto an Eppendorf Mastercycler^®^ personal using conditions provided in the manual. This resulted in the conversion of mature miRNAs into cDNA. Equal amounts of cDNA were used for subsequent polymerase chain reaction (PCR). Since there are no validated reference genes for miRNA qPCR in GS, we used RNU6-2 as control for the normalization of miRNA expression \[[@CR15], [@CR16]\]. Samples from each subject with primers for the target and reference genes were loaded separately in triplicates in a 96-well plate. StepOnePlus™ Real-Time PCR System was used. At the end of the PCR run, a melting curve analysis was also performed using miScript SYBR^®^ Green PCR Kit by Qiagen, using cDNA prepared in the previous reverse transcription to verify purity. We used our age-matched controls as the control sample to perform our ΔΔCt calculations. The intestinal atresia and necrotizing enterocolitis groups served as our comparison groups to determine whether miRNA-143/145 expression was elevated in GS. Relative quantification was performed with the data from the PCR instrument. We decided to use the comparative method of relative quantification (ΔΔCt method), which relies on comparing differences in Ct values. Before using this method, a validation experiment was performed to make sure that the amplification efficiencies of both target and reference are comparable.

Data Analysis {#Sec13}
-------------

All data are expressed as mean + SEM using a commercial statistical software program (NCSS, Kaysville, UT). Statistical significance of differences among groups was determined by either a Student's *t* test or analysis of variance (ANOVA) followed by Duncan's and Tukey--Kramer multiple comparison tests where applicable. A *p* value \<0.05 was considered significant (*n* = 4--6).

Results {#Sec14}
=======

Expression of TGF-β Isoforms in Human Intestinal Smooth Muscle in Infants with GS {#Sec15}
---------------------------------------------------------------------------------

To investigate our hypothesis that intestinal smooth muscle cells were capable of expressing TGF-β3 in GRID, we stained intestinal tissue from human GS infants for all TGF-β isoforms. TGF-β3 immunostaining (pixel units: control---2,324,004 ± 382,219 and GS---4,801,475 ± 330,388\*) was significantly increased compared with TGF-β1 and 2 in GS infants compared with controls. Compared with control infants, TGF-β3 and α-actin (Fig. [1](#Fig1){ref-type="fig"}b) co-localized to the intestinal smooth muscle cells in infants with GS.Fig. 1Expression of TGF-β isoforms in the intestinal smooth muscle. **a** Calculated mean pixel units of TGF-β1, 2 and 3 from intestinal tissue sections of human infants with gastroschisis (GS) and premature infant controls, expressed as mean ± SEM. Groups were compared by a Student's *t* test for each TGF-β group. **b** Representative photomicrographs (magnification ×20) from intestinal tissue sections of human infants with gastroschisis (GS) and premature infant controls are depicted and show the immunoreactivity of TGF-β3 (*green*) and α-actin (*red*) in the intestinal smooth muscle layers of the intestine. Co-localization of TGF-β3 and α-actin (*yellow*) is also seen in the intestinal smooth muscle layer of GS infant intestine (*n* = 7)

TGF-β3 Promotes Collagen Gel Contraction in Intestinal Smooth Muscle Cells {#Sec16}
--------------------------------------------------------------------------

To explain the intestinal smooth muscle dysfunction seen in GRID, we hypothesized that TGF-β3 signals intestinal smooth muscle cell hyper-contractility. To determine whether TGF-β3 promotes cell contractility, we used a collagen gel matrix assay to measure intestinal smooth muscle cell contraction. As depicted in Fig. [2](#Fig2){ref-type="fig"}a, TGF-β3 contributed to more gel contraction compared with TGF-β1 or 2 (*p* = 0.001). At 24 h, TGF-β3 caused a 249 % (*p* = 0.008) increase in gel contraction compared with cells not exposed to TGF-β3 (Fig. [2](#Fig2){ref-type="fig"}b). By 72 h, TGF-β3 continued to cause intestinal smooth muscle cell contraction at a 99 % increase over cells not exposed to TGF-β3 (*p* = 0.005).Fig. 2TGF-β3 promotes increased contraction of the collagen gel matrix. **a** Line diagrams show cell contraction in a collagen gel matrix (mean ± SEM) with FBS ± TGF-β1, 2 or 3 over 6, 24 and 72 h, respectively. Intestinal smooth muscle cell contraction is significantly increased in a time-dependent manner on exposure to TGF-β3. Groups were compared by ANOVA for each TGF-β group at each time point. **b** *Line diagrams* show percentage of cell contraction in a collagen gel matrix (mean ± SEM) with FBS ± TGF-β3 over 6, 24 and 72 h. Intestinal smooth muscle cells exposed to TGF-β3 became more contracted as time increased. Experimental groups were compared by a Student's *t* test

TGF-β3 Promotes Intestinal Dysmotility {#Sec17}
--------------------------------------

Next, we investigated the dose-dependent effects of TGF-β3 on intestinal motility in rats using FITC-Dextran intestinal transit. The data depicted in Fig. [3](#Fig3){ref-type="fig"} demonstrate that the average mean geometric center (MGC) in high-dose TGF-β3 rats (6.7 ± 0.2\*\*, *p* \< 0.05) was significantly decreased compared with Sham (9.0 ± 0.1) and low-dose TGF-β3 (8.0 ± 0.3\*) rats. Low-dose TGF-β3 rats had significantly decreased intestinal transit compared with Sham rats (*p* \< 0.05).Fig. 3Administration of TGF-β3 into the peritoneal cavity decreases intestinal motility. *Bar diagrams* show intestinal transit as the mean geometric center in the small intestine (mean ± SEM). At 12 h after i.p. injection of TGF-β3, intestinal transit is significantly impaired in a dose--response manner in the animals given i.p. TGF-β3. Experimental groups were compared by ANOVA with a Tukey--Kramer test

TGF-β3 Up-Regulates the Contractile Phenotypic Gene Expression in Intestinal Smooth Muscle Tissue and Cell Culture {#Sec18}
------------------------------------------------------------------------------------------------------------------

Because miRNA is known to survive the degradation process that occurs from embedding tissue in paraffin, we used LCM to isolate the intestinal smooth muscle layer from infants with and without GS. As shown in Fig. [4](#Fig4){ref-type="fig"}, smooth muscle contractile markers miRNA 143 & 145 (Relative miRNA levels l: 12 ± 4\* & 19 ± 5\*) are elevated in the GS infants compared to infants with Atresia (relative miRNA levels: 1 ± 0.2\* & 2 ± 0.6) and NEC (relative miRNA levels: 12 ± 0.4\* & 5 ± 2). When intestinal smooth muscle cells are exposed to TGF-β3 in culture, they also demonstrated a significant increase in the contractile miRNA markers 143 & 145 (Fig. [5](#Fig5){ref-type="fig"}a).Fig. 4Expression of contractile micro-RNA markers in human intestinal smooth muscle. Calculated mean relative miRNA levels of miRNA-143 (**a**) and miRNA-145 (**b**) from intestinal tissue sections of human infants with gastroschisis (GS), intestinal atresia (IA), necrotizing enterocolitis (NEC) and age-matched premature infant control tissue, expressed as mean ± SEM. Groups were compared by ANOVA. Intestinal tissue from the GS patients had significantly elevated levels of miRNA 143 & 145 compared with the other groupsFig. 5TGF-β3 promotes the expression of contractile micro-RNA markers in human intestinal smooth muscle. **a** *Line diagrams* show the contractile phenotype gene expression (mean ± standard error of the mean \[SEM\])) with FBS (**a**) and FBS ± TGF-β3 (**b**) over 6, 24 and 72 h. Contractile marker: ϒ-smooth muscle actin (ACTG2), calponin (CNN1), smooth muscle myosin heavy chain (MYH11) and smooth muscle-22α (TAGLN). Intestinal smooth muscles exposed to TGF-β3 have a significantly higher expression of contractile genes at all-time points. These data support that hISMCs exposed to TGF-β3 have a contractile phenotype

It is known that intestinal smooth muscle cells in culture over time switch from a contractile to a synthetic phenotype. To investigate whether our intestinal smooth muscle cells underwent this phenotypic gene change after TGF-β3 exposure, we evaluated known contractile and synthetic smooth muscle markers. Intestinal smooth muscle cells exposed to TGF-β3 expressed higher contractile protein markers compared with cells exposed to FBS only (Fig. [5](#Fig5){ref-type="fig"}b). As depicted in Fig. [6](#Fig6){ref-type="fig"}, there was no change in the intestinal smooth muscle cell synthetic gene expression on exposure to TGF-β3.Fig. 6TGF-β3 does not exhibit a synthetic protein gene expression profile. *Line diagrams* show the synthetic phenotype gene expression (mean ± standard error of the mean \[SEM\])) with FBS (**a**) and FBS ± TGF-β3 (**b**) over 6, 24 and 72 h. Synthetic markers: L-caldesmon (CALD1), non-muscle myosin heavy chain IIB (MYH10) and vimentin (VIM). There is no significant difference in the synthetic phenotypic gene expression when hISMCs are exposed to TGF-β3

Discussion {#Sec19}
==========

We previously demonstrated that non-occlusive mesenteric hypertension (NMH) causes intestinal dysfunction and inflammation similar to infants with GRID. However, there is a paucity of reports on the mediators that contribute to the smooth muscle dysfunction in GRID. In this report, we show for the first time that the pro-inflammatory cytokine, TGF-β3, was significantly elevated in the intestinal smooth muscle layer in human GS compared with control subjects. Our data further demonstrated that TGF-β3 was associated with increased intestinal smooth muscle cell contractility, global intestinal dysfunction and increased smooth muscle cell markers of contractile gene expression.

The tissue-level biomechanical force from shear stress, strain or hypertension is known to signal inflammation and has recently been shown to participate in smooth muscle remodeling and phenotypic switching \[[@CR14], [@CR17]\]. Smooth muscle migration, hypertrophy and hyperplasia are prominent features in organ remodeling processes after injury in smooth muscle-related diseases such as asthma and atherosclerosis remodeling \[[@CR18], [@CR19]\]. The GS abdominal wall defect and NMH model (NMH-simulated model of the abdominal wall defect in animals) are biomechanical forces that produce mesenteric venous hypertension that results in intestinal inflammation and dysfunction \[[@CR1], [@CR8], [@CR20]\]. In this report, we provide new evidence that TGF-β3 impairs intestinal transit in a dose-dependent manner similar to that seen in infants and our animal model. Our group has previously demonstrated that NMH contributed to a significant decrease in intestinal contractility prior to stimulation of the enteric nervous system with carbachol \[[@CR8]\]. The addition of carbachol resulted in minimal improvement in NMH-induced intestinal contractile dysfunction. These findings suggested that NMH may contribute to a primary smooth muscle dysfunction that impaired transit and contractile function. Although our NMH model had decreased intestinal contractility that partially recovered, our current cell culture experiments using TGF-β3 stimulation showed increased intestinal smooth muscle cell contraction. Gawaziuk et al. \[[@CR21]\] reported that TGF-β was responsible for super-contractile smooth muscle cell states that produced non-specific hyper-reactivity of airways in asthmatic patients. In the erectile dysfunction literature, abnormal contractile events in vascular smooth muscle cells of the penis produce end-organ dysfunction \[[@CR22], [@CR23]\]. Elevated intestinal smooth muscle cell contraction may explain why the NMH model exhibited decreased intestinal contractility without full recovery and decreased intestinal length.

Cellular signaling and regulation of calcium and myosin light chain kinase are important in generation and maintenance of smooth muscle cell contraction \[[@CR24], [@CR25]\]. Well-known signaling pathways that participate in smooth muscle contraction include RhoA/Rho-kinase and G-protein-coupled receptor proteins \[[@CR23], [@CR26]\]. While a paucity of data exists on TGF-β3's role in intestinal smooth muscle contraction, several studies have demonstrated the ability of myofibroblasts and smooth muscle cells to express TGF-β3 \[[@CR27]--[@CR29]\]. Recent data support that TGF-β is capable of autocrine signaling which has been shown to produce airway smooth muscle hyperplasia \[[@CR30], [@CR31]\]. Our results show that TGF-β3 co-localized with smooth muscle actin, which suggests that the intestinal smooth muscle is capable of producing TGF-β3. The intestinal smooth muscle cell could serve as a source of TGF-β3 in the intestinal smooth muscle layer of GS infants acting in an autocrine/paracrine fashion to further exacerbate GRID.

In summary, we demonstrated that the TGF-β3 contributed to intestinal dysfunction at the organ level, increased contraction at the cellular level and elevated contractile gene expression at the molecular level. This hyper-contractile response may play a role in the persistent intestinal dysfunction seen in GRID.
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